Histamine Dihydrochloride

• In vivo biological standardization of Dermatophagoides allergen extracts. Not authorised
  2024-514108-15-00 Phase II 1 country Advanced Outcomes Research S.L.; Asac Pharmaceutical Inmunology S.A.
• In vivo biological standardization of Blomia tropicalis allergen extract. Pending
  2025-520711-14-00 Phase II 1 country Asac Pharmaceutical Inmunology S.A.
• In vivo biological standardization of Lepidoglyphus destructor allergen extract Pending
  2025-520753-37-00 Phase II 1 country Advanced Outcomes Research S.L.; Asac Pharmaceutical Inmunology S.A.
• D. pteronyssinus and D. farinae allergen extracts. Study of the sensitivity and specificity of the prick test diagnostic preparation Pending
  2025-522469-31-00 Phase III 1 country Inmunotek S.L.
• Allergen extract of Lepidoglyphus destructor. Study of the sensitivity and specificity of the diagnostic preparation in prick tests Pending
  2025-523426-40-00 Phase III 1 country Inmunotek S.L.
• In vivo biological standardization of Olea europaea allergen extracts. Pending
  2025-523866-26-00 Phase II 1 country Asac Pharmaceutical Inmunology S.A.
• “In vivo” biological standardization of the allergenic extracts Dermatophagoides pteronyssinus (DPT) and Dermatophagoides farinae (DF) in pa… Pending
  2026-525628-13-00 Phase II 1 country Probelte Pharma S.L.
• A prospective, randomized, double-blind, placebo-controlled, multicentre, dose-finding clinical trial with polymerised mannan-conjugated all… Recruiting
  2025-524580-21-00 Phase II/III 1 country Inmunotek S.L.
• PANCEP-1 Recruiting
  2023-506979-10-00 Phase I/II 1 country Vaestra Goetalandsregionen
• Long-term clinical trial of PQ Grass in paediatric subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass poll… Recruiting
  2023-508520-36-00 Phase III 7 countries Allergy Therapeutics (UK) Limited
• A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy with DBV712 250 µg in 1-thr… Ended
  2025-521697-34-00 Phase III 4 countries Dbv Technologies
• In vivo biological standardization of Dermatophagoides allergen extracts. Ended
  2024-514108-15-01 Phase II 1 country Asac Pharmaceutical Inmunology S.A.
• ViaskinTM Peanut Immunotherapy Trial to Evaluate Safety, Simplicity and Efficacy (VITESSE) Ended
  2022-502110-85-00 Phase III 5 countries Dbv Technologies
• Determination of Blomia tropicalis allergen extract in prick test units Ended
  2024-515169-33-00 Phase II 1 country Inmunotek S.L.
• Phleum pratense and Dactylis glomerata allergen extracts. Determination of the in vivo histamine equivalent prick test units. Ended
  2024-514215-98-00 Phase II 1 country Inmunotek S.L.
• A prospective, randomized, double-blind placebo-controlled multicentre trial with mannan-conjugated birch pollen allergoids administered sub… Ended
  2024-515717-17-00 Phase III 1 country Inmunotek S.L.
• Lepidoglyphus destructor extract. Determination of in vivo allergenic potency in histamine equivalent prick testing units (HEP). Ended
  2023-509541-13-00 Phase II 1 country Inmunotek S.L.
• BIOLOGICAL STANDARDISATION OF ALLERGENIC EXTRACTS OF MITES TO DETERMINE BIOLOGICAL ACTIVITY (IN HEP UNITS) IN SENSITIVISED PATIENTS. Ended
  2024-513834-40-01 Phase II 1 country Diater Laboratorio De Diagnostico Y Aplicaciones Terapeuticas S.A.
• Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from Olea europaea pollen a… Ended
  2024-511383-88-00 Phase II/III 1 country ROXALL Medizin GmbH
• A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutane… Ended
  2023-504942-75-01 Phase III 6 countries HAL Allergy B.V.
• Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from grass pollen allergy Ended
  2023-505880-35-00 Phase II/III 1 country ROXALL Medizin GmbH
• Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from birch pollen allergy Ended
  2023-505567-37-00 Phase II/III 1 country ROXALL Medizin GmbH

Showing 1–22 of 22 trials